A novel combinatorial cancer immunotherapy

Poly-IC and blockade of the PD-1/PD-L1 pathway

Toshihiro Nagato, Esteban Celis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

Original languageEnglish (US)
Article numbere28440
JournalOncoImmunology
Volume3
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Immunotherapy
Cell Death
Neoplasms
Blocking Antibodies
T-Lymphocytes
Therapeutics

Keywords

  • Cancer immunotherapy
  • Colon cancer
  • Lung cancer
  • Melanoma
  • PD-1
  • PD-L1
  • Poly-IC

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

A novel combinatorial cancer immunotherapy : Poly-IC and blockade of the PD-1/PD-L1 pathway. / Nagato, Toshihiro; Celis, Esteban.

In: OncoImmunology, Vol. 3, No. 5, e28440, 01.01.2014.

Research output: Contribution to journalArticle

@article{5126d2744f194e949a0bcf9358bf66bd,
title = "A novel combinatorial cancer immunotherapy: Poly-IC and blockade of the PD-1/PD-L1 pathway",
abstract = "A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.",
keywords = "Cancer immunotherapy, Colon cancer, Lung cancer, Melanoma, PD-1, PD-L1, Poly-IC",
author = "Toshihiro Nagato and Esteban Celis",
year = "2014",
month = "1",
day = "1",
doi = "10.4161/onci.28440",
language = "English (US)",
volume = "3",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "5",

}

TY - JOUR

T1 - A novel combinatorial cancer immunotherapy

T2 - Poly-IC and blockade of the PD-1/PD-L1 pathway

AU - Nagato, Toshihiro

AU - Celis, Esteban

PY - 2014/1/1

Y1 - 2014/1/1

N2 - A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

AB - A non-antigen specific immunotherapy consisting of repeated co-administration of poly-IC and blocking antibodies targeting the programmed cell death-1 (PD-1) pathway dramatically inhibits tumor development in several mouse models of cancer. Tumor-reactive CD8+ T cells mediate the antitumor effects mediated by PD-1 blockade. This therapeutic avenue can be readily translated to cancer patient treatment regimens.

KW - Cancer immunotherapy

KW - Colon cancer

KW - Lung cancer

KW - Melanoma

KW - PD-1

KW - PD-L1

KW - Poly-IC

UR - http://www.scopus.com/inward/record.url?scp=84904045263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904045263&partnerID=8YFLogxK

U2 - 10.4161/onci.28440

DO - 10.4161/onci.28440

M3 - Article

VL - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 5

M1 - e28440

ER -